Development and Validation of the TELL Score (Pleural Thickening (T), Fluid Echogenicity (E), Loculations (L), and Laterality (L)): A Structured Sonographic Approach to Classifying Pleural Effusions

TELL评分(胸膜增厚(T)、液体回声(E)、分隔(L)和侧别(L))的开发和验证:一种用于对胸腔积液进行分类的结构化超声方法

阅读:1

Abstract

INTRODUCTION: Pleural effusion classification guides management, but Light's criteria require invasive sampling and laboratory infrastructure and may be prone to misclassifications. A rapid, bedside alternative is needed, particularly in resource-limited settings.  Aim: This study aimed to develop and validate a novel, four-point sonographic scoring system, the TELL (pleural thickening (T), fluid echogenicity (E), loculations (L), and laterality (L)) score, for differentiating pleural effusions at the bedside. MATERIALS AND METHODS: This is a prospective observational study conducted at Saveetha Medical College Hospital, a tertiary care centre in South India from March 2021 to February 2022. Seventy-four adult patients with pleural effusions underwent thoracic ultrasonography, assessing four "TELL" parameters: pleural thickening (≥3 mm), fluid echogenicity, laterality (unilateral effusions), and presence of loculations. Each positive finding scored one point (range 0-4). Diagnostic performance was compared against Light's criteria using diagnostic indices and receiver operator characteristic (ROC) curve analysis. RESULTS: Among 74 participants (mean age 58.7±17.2 years; 59.5% male), 64 effusions (86.5%) were exudates, mainly tuberculosis and malignancy. Sonographic features were more common in exudates: pleural thickening (95.3%), echogenicity (98.4%), loculations (29.7%), and unilateral distribution (85.9%; all p < 0.01). At cut-off ≥2, the TELL score achieved 98.4% sensitivity, 40% specificity, negative predictive value (NPV) 80%, and area under the curve (AUC) 0.79 (95% confidence interval CI: 0.64-0.94) Conclusions: The TELL score is a rapid, non-invasive screening tool with high sensitivity and NPV, particularly useful when lab confirmation is delayed or unavailable. Multicentre validation and reliability studies in larger cohorts are needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。